Choukri Ben Mamoun
Choukri Ben Mamoun, who has made groundbreaking discoveries in microbial pathogenesis, diagnostics, and therapeutic interventions, was recently appointed the John F. Enders Professor of Medicine (Infectious Diseases), effective immediately. The appointment is for a term of 10 years, renewable by the dean of the Yale School of Medicine (YSM).
Ben Mamoun is also professor of microbial pathogenesis and pathology at YSM and has an affiliation with the Yale Institute for Global Health.
He joined the Yale faculty in 2009 after serving roles at Washington University, the Howard Hughes Medical Institute, and the University of Connecticut Health Center.
At Yale he became principal investigator with a focus on the biology and therapy of the protozoan parasites that cause human malaria and babesiosis.
In his work, Ben Mamoun has elucidated new pathways that can be targeted to treat or prevent infectious diseases caused by apicomplexa, including Plasmodium that cause malaria, and Babesia that cause babesiosis. This has led to new classes of experimental compounds that can be used to combat these important mosquito- and tick-borne illnesses.
His research has earned support from organizations such as the Burroughs Wellcome Fund, the National Institutes of Health (NIH), the U.S. Department of Defense (DOD), the Gates Foundation, and the Global Lyme Alliance. His current research program is supported by nine active grants, including from the NIH and various foundations. He has also served on numerous influential review panels, including for the NIH, the DOD, the Wellcome Trust, the Swedish Research Council, and the Israel Science Foundation.
Ben Mamoun’s scholarship has appeared in more than 138 publications in leading scientific journals, including Nature, Science, Cell, and the Proceedings of the National Academy of Sciences. His expertise and leadership extend beyond his research, as he has served on various institutional committees and mentored over 100 students, postdoctoral fellows, and MDs.
In addition to his research and educational contributions, he has demonstrated a commitment to translational science and entrepreneurship. As the founder of Curatix, LLC, and Virtus Therapeutics Corporation, he has successfully bridged the gap between academic research and real-world applications, bringing innovative diagnostic and therapeutic solutions to market.
Ben Mamoun earned his M.S. and D.E.A. (diplôme d’études approfondies) in molecular microbiology from the University Paris XI and his Ph.D. in molecular microbiology from the University of Paris XI and the Insitut National Agronomique Paris-Grignon.
